In this issue:
Priorities and expectations regarding multidisciplinary ILD clinic attendance
Service to connect pulmonary fibrosis patients with peers
Mortality and sarcopenia in IPF patients receiving antifibrotics
Heightened cancer risk in IPF patients
Association between anticoagulation and survival in ILD
Adding inhaled N-acetylcysteine to pirfenidone accelerates FVC decline in IPF
Antimicrobials do not reduce hospitalisations or death in IPF
PPIs ineffective in IPF
Pirfenidone in progressive fibrotic ILDs other than IPF
Serious infection risk in sarcoidosis
Please login below to download this issue (PDF)